Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)

Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2020
This is a multicenter Phase III, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of tildrakizumab in Subjects with Active Psoriatic Arthritis I (INSPIRE 1)
Epistemonikos ID: f466f3eb4fdb461c8595354684718258532fbeba
First added on: Feb 15, 2022